ArticleMolecular oncology2022
Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Article in Molecular oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 8 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non-Small Cell Lung Cancer: An Updated Meta-Analysis.JCO precision oncology · 2025Pooled it
- Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.EBioMedicine · 2024Pooled it
- Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Prognostic value of circulating tumor DNA in operable non-small cell lung cancer: a systematic review and reconstructed individual patient-data based meta-analysis.BMC medicine · 2023Pooled it
- Clinical significance of circulating tumor DNA in localized non-small cell lung cancer: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis.JNCI cancer spectrum · 2023Pooled it
- Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.BMC medicine · 2023Pooled it
- Circulating tumour cells in patients with lung cancer universally indicate poor prognosis.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- Review
- Liquid biopsy in bladder cancer: towards precision oncology.Journal of translational medicine · 2026Review
- [Clinical Frontiers and Applications Progress of ctDNA in Precision Treatment of Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- New proteomic signature in circulating extracellular vesicles from tumor-draining and peripheral veins of patients with lung adenocarcinoma.Cancer cell international · 2026Article
- Defining the role of PET/CT in posttreatment surveillance for non-small cell lung cancer.Journal of thoracic disease · 2026Article
- Article
- Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting.Discover oncology · 2026Review
- Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.Translational lung cancer research · 2025Article
- Review
- Circulating tumor DNA in lung cancer: a bibliometric analysis of studies published from 2001 to 2024.Journal of thoracic disease · 2025Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in patients with non-small-cell lung cancer (NSCLC). However, little is known about its dynamics during and after tumor resection, or its potential for predicting clinical outcomes. Here, we applied a targeted-capture high-throughput sequencing approach to profile ctDNA at various disease milestones and assessed its predictive value in patients with early-stage and locally advanced NSCLC. We prospectively enrolled 33 consecutive patients with stage IA to IIIB NSCLC undergoing curative-intent tumor resection (median follow-up: 26.2 months). From 21 patients, we serially collected 96 plasma samples before surgery, during surgery, 1-2 weeks postsurgery, and during follow-up. Deep next-generation sequencing using unique molecular identifiers was performed to identify and quantify tumor-specific mutations in ctDNA. Twelve patients (57%) had detectable mutations in ctDNA before tumor resection. Both ctDNA detection rates and ctDNA concentrations were significantly higher in plasma obtained during surgery compared with presurgical specimens (57% versus 19% ctDNA detection rate, and 12.47 versus 6.64 ng·mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.